A range of expertise that turns opportunities into solutions
We provide essential capabilities to in-license a product at any stage of development and then mobilize the resources needed to move the product toward regulatory approval and commercialization.
A company whose commitment to excellence permeates everything we do, Forest has been recognized for its sound business practices, including being named by Forbes as the best managed company in the drug and biotechnology industry in 2004.
Research
Our research organization includes nearly 900 professionals with the expertise needed to complete all phases of drug development – from investigating the therapeutic potential and safety of early-stage molecules to conducting the clinical trial research needed to bring important therapies such as Lexapro® (escitalopram oxalate) and Namenda® (memantine HCl) to the U.S. market. Our licensing strategy and research capabilities have given us a growing and diverse pipeline. We continue to develop our key therapeutic franchises (central nervous system, cardiovascular and respiratory) and have expanded our development program to include agents for inflammation and pain.
Regulatory
Forest’s regulatory department has extensive experience meeting drug development and marketing approval requirements, including Investigational New Drug/New Drug Applications (IND/NDA) and with Quality Assurance/Quality Control (QA/QC) processes. Since 1996, we have filed more than a dozen NDA/sNDAs. Our regulatory team has shepherded drug submissions across a range of therapeutic areas including Lexapro for depression and generalized anxiety disorder, Namenda for moderate to severe Alzheimer’s disease, and Combunox® (oxycodone HCl and ibuprofen) for the short-term management of acute, moderate to severe pain.
Marketing
We have a successful track record of launching and promoting products in intensely competitive markets in the United States. Our 2002 launch quickly established Lexapro as one of the leading antidepressants prescribed in the United States making it the fifth largest drug launch*. Namenda became the number two product in its category in less than three months after its 2004 launch. Benicar® launched as the seventh ARB and has become the fastest-growing ARB. It is now third in its class. Campral became the number one product for new prescriptions in less than five months after its launch. Our marketing launches of Namenda, Lexapro, Benicar, and Celexa® have been recognized for marketing excellence from various industry associations.
Sales Force
The Forest sales organization is comprised of 2,700 representatives in the United States. An industry-leading sales force ranked at the top for productivity and sales call quality, our sales forces reach primary care physicians, psychiatrists, neurologists, cardiologists, orthopedic surgeons, pain specialists, hospitals, managed care organizations and senior care providers nationwide. Forest is consistently ranked as one of the best companies to sell for by Selling Power magazine.
Manufacturing and Distribution
Forest manufactures pharmaceuticals in liquid and solid dosage forms using state-of-the-art tablet and liquid production equipment. Our fully automated distribution operations ship our products to wholesalers and distributors throughout the United States.
*Source: IMS NPA Plus. Based on retail TRx volume one year post launch for products launched after June 1994
|